Release testing involves both standard potency assays and unique assays (particle size, NA activity) developed to ensure the physical, chemical, and biological stability of this type of vaccine.
This article presents ongoing research at VIDO-InterVac for the development of safer and more effective adjuvants. These include adjuvants that stimulate innate immunity in the body and combination adjuvants.
In this question-and-answer discussion of "generic" biologics, the authors contend small changes in manufacturing of biologics dramatically affect the safety and efficacy of the therapeutic molecule.
A step-by-step approach is essential for successful implementation.
Clinical studies have shown that treatment with thymosin alpha 1 increases response to vaccination.
Wet testing of microbial fermenters allows for a greater understanding of the equipment's capabilities.
By considering stability as part of the cell line selection and cell banking paradigm, we can ensure that instability problems are not observed during clinical or commercial manufacturing.
New technologies and adaptations of existing technologies can improve platform processes.
A systematic approach facilitates formulation component selection.
Best methods to maximize product yield and membrane lifetime to enhance a tangential flow filtration process.
How to successfully balance patient safety with supply-chain management
Engaging executive leadership in the quality process is the key to compliance success.
Robust packing procedures can improve process performance and increase resin lifetime.
Vaccine process development is complex, and so are the documents required before clinical trials begin. Technical writers and editors can effectively coordinate the timely authoring, reviewing, and auditing of regulatory documents, minimizing filing delays.
When platform processes are applied to fusion molecules, innovation and flexibility are needed.
Emerging therapies pose challenges for standardizing QC.
A new method for MAb purification.
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
A twin-column periodic countercurrent capture process that combines an efficient sequential, countercurrent loading process with a minimal twin-column hardware configuration is described.
An off-the-shelf, single-use perfusion system.
Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Challenges of vaccine development include regulatory, technical, and manufacturing hurdles in translating a vaccine candidate into a commercial product.
How to successfully balance patient safety with supply-chain management
This article discusses the potential of MIS416 adjuvant, a vaccine adjuvant and immunogen co-delivery system, to provide adequate immunostimulation to overcome host factors that may limit the success of therapeutic vaccines.
Avoid manufacturing failures by effective viral inactivation.
Avoid manufacturing failures by effective viral inactivation.